Tildacerfont
Sponsors
Spruce Biosciences Inc., Spruce Biosciences
Conditions
21-OHDClassic Congenital Adrenal HyperplasiaCongenital Adrenal HyperplasiaPolycystic Ovary Syndrome
Phase 2
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH
TerminatedNCT05128942
Start: 2021-12-10End: 2025-01-31Updated: 2025-12-24
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
TerminatedNCT05370521
Start: 2022-05-15End: 2023-08-31Updated: 2025-10-09
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia
CompletedCTIS2023-503770-21-00
Start: 2021-01-05End: 2024-03-24Target: 26Updated: 2024-03-29
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont)
in Reducing Supraphysiologic Glucocorticoid Use in Adult Subjects with Classic Congenital Adrenal Hyperplasia
CompletedCTIS2023-503771-13-00
Start: 2021-01-28End: 2024-12-12Target: 44Updated: 2024-12-18